Wang Haowen, Zhan Yu, Jin Jingjing, Zhang Chunhong, Li Wenfeng
Department of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.
Oncol Rep. 2023 Oct;50(4). doi: 10.3892/or.2023.8611. Epub 2023 Aug 18.
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the cell migration and invasion images shown in Figs. 3B and D and 6C were strikingly similar to data that had already appeared in an article written by different authors at different research institutes [Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L, Lu K, Tao T and Zhang X: miR‑195 inhibits EMT by targeting FGF2 in prostate cancer cells. PLoS One 9: e0144073, 2015]. Owing to the fact that the contentious data in the above article had already been published prior to its submission to , the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 37: 3305‑3312, 2017; DOI: 10.3892/or.2017.5604].
在本文发表后,一位关注此事的读者提醒编辑注意,图3B、D和6C中所示的某些细胞迁移和侵袭图像与不同研究机构的不同作者撰写的一篇文章中已经出现的数据惊人地相似[Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L, Lu K, Tao T和Zhang X:miR-195通过靶向FGF2抑制前列腺癌细胞中的EMT。《公共科学图书馆·综合》9:e0144073,2015]。由于上述文章中有争议的数据在提交给本期刊之前就已经发表,编辑决定将本文从本期刊撤回。已要求作者对这些问题作出解释,但编辑部未收到答复。编辑就由此造成的不便向读者表示歉意。[《肿瘤学报道》37:3305 - 3312,2017;DOI:10.3892/or.2017.5604]